Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Tian, Wei ^a   Ding, Wenping ^a   Kim, Sungkyoung ^a   Zheng, Leizhen ^a   Zhang, Li ^a   Li, Xiaoping ^a   Gu, Jianchun ^a   Zhang, Lian ^a   Pan, Minggui ^b   Chen, Siyu ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; PEMETREXED; VANDETANIB;

ADVANCED CANCER; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; HUMAN; HYPERTENSION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; META ANALYSIS; MONOTHERAPY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SYSTEMATIC REVIEW; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, BIBLIOGRAPHIC; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84879813094     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067929     Document Type: Article

References (26)

1. Siegal R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551.
3. Lima AB, Macedo LT, Sasse AD, (2011) Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Plos One 6: e22681.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
5. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, et al. (2006) Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: A rational approach for muti-target anticancer therapy. Ann Oncol 17: vii109-114.
6. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, et al. (2009) Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15: 3484-3494.
7. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, et al. (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655.
8. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, et al. (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284-7290.
9. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
12. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, et al. (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-linetreatment for advanced non-small-cell lung cancer. J Clin Oncol 26: 5407-5415.
13. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, et al. (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treatednon small-cell lung cancer. J Clin Oncol 25: 4270-4277.
14. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, et al. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advancednon-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11: 619-626.
15. de Boer RH, Arrieta Ó, Yang CH, Gottfried M, Chan V, et al. (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lungcancer: a randomized, double-blind phase III trial. J Clin Oncol 29: 1067-1074.
16. Cesare Gridelli, Silvia Novello, Nicoletta Zilembo, Paolo Foa, Adolfo G Favaretto, et al. (2012) Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714). J Clin Oncol 30, 2012 (suppl; abstr 7550).
17. Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, et al. (2013) Chemotherapy plus Vandetanib or Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of Four Randomised Controlled Trials. Clin Oncol (R Coll Radiol) 25: e7-e15.
18. Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME, (2012) Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 97: 1125-1133.
19. Fischer C, Carmeliet P, Conway EM, (2006) VEGF inhibitors make blood. Nat Med 12: 732-734.
20. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, et al. (2009) Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15: 3600-3609.
21. Riely GJ, Marks J, Pao W, (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-205.
22. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742.
23. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388.
24. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128.
25. Mao C, Qiu LX, Liao RY, Du FB, Ding H, et al. (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69: 272-278.
26. Guan JL, Zhong WZ, An SJ, Yang JJ, Su J, et al. (2012) KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy. Ann Surg Oncol 20: 1381-1388.